Kwangdong Pharmaceutical has received an administrative penalty for illegally advertising Contrav (ingredient: naltrexone/bupropion).
The Ministry of Food and Drug Safety said it has imposed a 35.1 million won ($32,292) fine on the drugmaker for inserting the ad of Contrav on Kwangdong Pharm’s “Medicare Service” leaflets, displayed at a waiting room of a hospital. The fine is equal to three months of sales suspension of the drug, the ministry said.
Kwangdong’s leaflet said, “Contrave, approved by the U.S. FDA and Europe’s EMA, is a non-narcotic obesity treatment, which can be taken for a long time due to low drug dependency.” It also said, “Contrav controls appetite and food cravings to help lose weight.”
The ministry considered such statements as an advertisement.
Under the Pharmaceutical Affairs Act’s Article 68, the government prohibits exaggerated advertisements of pharmaceutical products. The regulations for the safety of pharmaceutical products state that if the ad is false, or even if it is true, it can be regulated if it can mislead or deceive consumers.
<© Korea Biomedical Review, All rights reserved.>